Saturn V Capital Management LP
Saturn V Capital Management LP reported 23 US-listed holdings worth $697.5 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Amylyx Pharmaceuticals Inc. (11.9%), Alumis Inc. (11.8%) and Abivax SA (9.9%). Against the quarter before, it opened 3 positions, added to 13, trimmed 6 and sold out of 1.
The 14 largest of its 23 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +115.2% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 3
- Trevi Therapeutics Inc. TRVI$19.6 million
- Sagimet Biosciences Inc. SGMT$11.4 million
- Vir Biotechnology, Inc. VIR$7.9 million
Added to 13
- Immix Biopharma Inc. IMMX+964,844 shares · +26%
- Celcuity Inc. CELC+88,414 shares · +31%
- Zura Bio Ltd ZURA+1.4 million shares · +184%
- Disc Medicine Inc. IRON+74,804 shares · +17%
- Amylyx Pharmaceuticals Inc. AMLX+274,216 shares · +6%
- Candel Therapeutics Inc. CADL+407,098 shares · +14%
- Pharvaris N V PHVS+112,720 shares · +9%
- Alto Neuroscience Inc. ANRO+93,830 shares · +105%
and 5 more in the table below
Trimmed 6
- Ovid Therapeutics Inc. OVID-3.5 million shares · -84%
- Alumis Inc. ALMS-286,632 shares · -9%
- Abivax SA ABVX-23,831 shares · -4%
- Monopar Therapeutics Inc. MNPR-33,650 shares · -10%
- Invivyd Inc. IVVD-2.6 million shares · -23%
- Jazz Pharmaceuticals plc JAZZ-2,023 shares · -1%
Sold out of 1
- Cogent Biosciences Inc. COGT$24.1 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc. AMLX | 4.6M | $83.0 million | 11.91% | +274.2K |
| Alumis Inc. ALMS | 2.9M | $82.0 million | 11.76% | -286.6K |
| Abivax SA ABVX | 518.9K | $69.1 million | 9.91% | -23.8K |
| Vaxcyte Inc. PCVX | 852.9K | $49.6 million | 7.11% | +28.4K |
| Immix Biopharma Inc. IMMX | 4.7M | $48.0 million | 6.89% | +964.8K |
| Pharvaris N V PHVS | 1.3M | $45.4 million | 6.52% | +112.7K |
| Jazz Pharmaceuticals plc JAZZ | 160.9K | $38.8 million | 5.56% | -2.0K |
| Celcuity Inc. CELC | 370.3K | $38.7 million | 5.55% | +88.4K |
| Disc Medicine Inc. IRON | 524.7K | $38.4 million | 5.50% | +74.8K |
| Candel Therapeutics Inc. CADL | 3.3M | $34.0 million | 4.88% | +407.1K |
| X4 Pharmaceuticals Inc. XFOR | 7.0M | $32.6 million | 4.67% | +516.7K |
| Monopar Therapeutics Inc. MNPR | 312.0K | $28.9 million | 4.14% | -33.6K |
| Dyne Therapeutics Inc. DYN | 1.1M | $23.5 million | 3.37% | +90.9K |
| Trevi Therapeutics Inc. TRVI | 1.1M | $19.6 million | 2.81% | new |
| Zura Bio Ltd ZURA | 2.1M | $12.4 million | 1.78% | +1.4M |
| Sagimet Biosciences Inc. SGMT | 1.5M | $11.4 million | 1.64% | new |
| Oculis Holding AG OCS | 684.9K | $9.5 million | 1.36% | +168.1K |
| Inhibikase Therapeutics Inc. IKT | 3.9M | $7.9 million | 1.13% | +5.6K |
| Vir Biotechnology, Inc. VIR | 770.6K | $7.9 million | 1.13% | new |
| Invivyd Inc. IVVD | 8.4M | $7.3 million | 1.05% | -2.6M |
| Alto Neuroscience Inc. ANRO | 182.8K | $4.8 million | 0.69% | +93.8K |
| Satellos Bioscience Inc. MSLE | 350.0K | $2.7 million | 0.39% | no change |
| Ovid Therapeutics Inc. OVID | 663.1K | $1.8 million | 0.26% | -3.5M |